upregulated transcript in human TF-1 erythroleukaemia cells upon GM-CSF deprivation and was reported as CCM disease gene in 2005. 7, 8 Pull-down and co-immunoprecipitation studies demonstrated that CCM3 forms a ternary complex with CCM1 and CCM2
in vitro and acts in intracellular networks with GCKIII serine/threonine kinases and other molecules. 9 Its inactivation in ECs is associated with altered autophagy, 10 impairment of the DLL4-Notch pathway, 11 activation of RhoA, 4 MEKK3-KLF2/4, 12-14 BMP/TGF-ß 15 signalling and increased exocytosis of angiopoietin 2. 16 Interestingly, the possibilities of the CRISPR/Cas9 system have not been used in these studies.
Since the clarification of the fundamental DNA interference mechanism and its first application for precise genome editing in mammalian cells, [17] [18] [19] the CRISPR/Cas9 system has become a versatile research tool. However, its efficiency is cell type-specific. Notably, CRISPR/Cas9-mediated gene disruptions in umbilical vein ECs, microvascular ECs, coronary artery ECs or ECs derived from cord blood colony-forming cells have almost exclusively been realized with viral delivery systems or plasmid transfections so far. [20] [21] [22] [23] [24] [25] [26] While the occurrence of potential off-target mutations may limit the use of both techniques, the delivery of the CRISPR/Cas9 components as ribonucleoprotein (RNP) complex can reduce off-target effects due to its short intracellular half-life. 27 Yu and co-workers have demonstrated that CRISPR/Cas9 RNPs can be used for genome editing in ECs. 28 Its efficiency has been reported to be significantly lower than in easy-to-transfect cells though.
In this study, we used a crRNA:tracrRNA:Cas9 RNP-based model were carried out at passage 6 (HUVEC), 27-31 (CI-huVEC) and 31-33 (hCMEC/D3). Acute CCM3 and miR-139-5p inhibition as well as adenoviral-mediated CCM3 re-expression are described in Data S1. Chemiluminometric VEGFR2/pVEGFR2 detection is described in Data S1.
| CRISPR/Cas9 mediated in vitro mutagenesis

| Real-time deformability cytometry (RT-DC) and immunofluorescence staining
RT-DC analysis was performed as described before. 30 
| Statistical analysis
Data were analysed with the GraphPad Prism software (v7.0a, GraphPad Software, La Jolla, USA) and presented as mean and standard deviation (SD) if not stated otherwise. Two-tailed, one sample t tests were used for normalized data. Two or more groups were compared with a two-tailed, Student's t test or one-and two-way ANOVA, respectively. Dunnett or Šidák corrections were applied for multiple comparisons. False discovery rate (FDR; q) was used for analysis of small RNA-sequencing data. Cell area and elastic moduli measurements were evaluated with the software ShapeOut (Zellmechanik Dresden) using linear mixed model comparisons. This approach allows to estimate the statistical significance of large datasets with multiple biological replicates. Briefly, linear mixed models separate RT-DC data into two contributions -a fixed effect summarizing the impact of the knockout on cell mechanical properties and a random effect due to systematic or random measurement bias.
After defining an additional model that lacks the fixed effect term a maximum likely hood ratio is calculated and the P value is derived. A P < 0.05 or q-value <0.05 was regarded as statistically significant.
| RESULTS
| Efficient CRISPR/Cas9-mediated CCM3 gene disruption in human ECs
To compare the efficiencies of viral and non-viral CRISPR/Cas9 delivery systems for CCM3 gene disruption in human ECs, we either Figure 1C and Figure S1 ).
Notably, the frequency of crRNA:tracrRNA:Cas9 RNP-induced CCM3 mutant alleles significantly increased during culture time.
Even in samples with low initial editing efficiencies, we observed CCM3 indel frequencies of up to 88% after four to eight weeks ( Figure 1D ). Furthermore, we noticed a marked shift in the mutational spectrum of crRNA:tracrRNA:Cas9 RNP-treated cells (Figure 1E ). While CCM3 mRNA expression was not reduced, CCM3
protein expression was completely abolished ( Figure 1F ,G). This observation is consistent with a previous CRISPR/Cas9 study targeting the CIITA locus in human ECs. Despite high genome editing efficiencies, no reduced CIITA transcript levels were found. 26 Since offtarget effects are a concern in CRISPR/Cas9 genome editing experiments, we screened potential off-target loci but found no CRISPR/ Cas9-induced variants (Table S1 ). In addition, we tested a second crRNA with a target sequence located in exon 6 which is shared by all CCM3 transcript variants and encodes for a part of the FAT-homology domain of CCM3. Increasing CCM3 mutant allele frequencies were also found in this second approach. From day 12 to 18 after crRNA:tracrRNA:Cas9 RNP transfection, indel frequencies had more than doubled from 17% (range: 8%-24%) to 38% (range: 27%-48%).
To exclude cell-type-specific effects, we also used primary
HUVECs and hCMEC/D3 cells. Consistent with our observations in CI-huVECs, the relative number of CCM3 indel alleles increased in both cell types after crRNA:tracrRNA:Cas9 RNP-mediated genome editing ( Figure S2 ).
| Increased clonogenicity of CCM3 -/-CI-huVECs
To support the hypothesis that CCM3-deficient ECs have a survival benefit, 58 CI-huVEC clones were established by limiting dilution within three weeks. These were derived from two 
| Reduced angiogenic response of CCM3
-/-
CI-huVECs
Little is known about the long-term effects of CCM3 deficiency in human ECs since most studies had focused on its acute inactivation so far. | 1775 elongation and migration were found ( Figure 4A,C) . While tube formation after 6 hours was unaffected (data not shown), the stability of tube-like structures after 18 hours was significantly reduced in CCM3-deficient CI-huVECs ( Figure 4B ). This instability could not be rescued by short-term CCM3 re-expression in CCM3 -/-CI-huVECs ( Figure S6 ). Of note, forced CCM3 expression in wild-type CIhuVECs also had an anti-angiogenic effect when compared to cells transduced with the recombinant GFP control adenovirus ( Figure S6 ).
This result was not completely unexpected since it is well known that overexpression and knockout of genes encoding for multiprotein complex components can cause the same phenotype due to a negative impact on stoichiometry or interaction of the other binding 
CCM3
-/-CI-huVECs demonstrated reduced Caspase-3 activities under standard culture conditions and also upon staurosporine treatment. Ac-DEVD-CHO = synthetic inhibitor for Caspase-3/7. F, Reduced senescence-associated β-galactosidase (SA-β-Gal) activity was observed in CCM3 -/-CI-huVECs under serum starvation. Scale bar ≙ 200 µm. G, The proliferation rate of CCM3 -/-CI-huVECs was slightly increased under serum starvation, whereas no difference was found in basal culture medium supplemented with 10% FCS and 25 ng/mL FGF-2 or 10% FCS alone. Data are presented as mean and SD (n = 3-8). Two-tailed, Student's t test was used for statistical analysis: *P < 0.05; **P < 0.01; ***P < 0.001 . Student's t test, one sample t test, linear mixed models (RT-DC) or two-way ANOVA with Šidák's multiple comparisons test were used for statistical analyses: *P < 0.05; **P < 0.01; ****P < 0.0001 partners. 34 Furthermore, adenoviral transduction alone proved to be pro-angiogenic, as it has been described in a previous report. Decreased number of meshes in tube formation assay (B) and migration rates (C) were also observed. Scale bars ≙ 1 mm. nc crRNA = nontargeting control crRNA, ctrl = untreated control. Data are presented as mean and SD (n = 3). One-way or Two-way ANOVA with Dunnett's multiple comparisons test and One-sample t test were used for statistical analysis: *P < 0.05; ****P < 0.0001 in hCMEC/D3 cells upon crRNA:tracrRNA:Cas9 RNP-induced CCM3 gene disruption ( Figure S7 and S8) . Figure 5A ). Since not only the mature miRNAs but in most cases also their corresponding precursor miRNAs (hsa-mir-493, hsamir-335, hsa-mir-216a, hsa-mir-217) were found to be regulated in the same direction, we considered miRNA biogenesis rather than miRNA degradation or turn-over to be controlled by CCM3.
Although the differences for the remaining corresponding strands did not pass the strict significance criteria, we also observed a trend towards decreased expression of hsa-miR-216a-5p (log 2 FC = -4.87;
q-value = 0.06), hsa-miR-335-5p (log 2 FC = −5.05; q-value = 0.07) and higher levels of hsa-miR-139-5p (log 2 FC = +2.42; q = 0.09).
Expression differences were verified by RT-qPCR analysis with miR-139-5p being upregulated nearly 4-fold ( Figure 5B ).
Prediction of miRNA-target interactions and pathway analysis
with the miRNet algorithm 37 demonstrated an enrichment of various gene ontology gene sets. Notably, "vasculature development"
(P = 0.006) and "ageing" (P = 0.007) were among the most significantly enriched gene ontology biological process terms. For example, the miR-217 level that has previously been reported as upregulated in senescent ECs 38 was found to be reduced by more than 95% in
CCM3
-/-CI-huVECs when compared to wild-type cells (129 vs.
RPM)
. Since ageing appears to be a major biological process influenced by CCM3 deficiency, we analysed the expression level of the identified miRNAs in high-passage, CRISPR/Cas9 RNP-treated and wild-type HUVECs and found miR-139-5p and miR-139-3p to be significantly upregulated in CCM3-deficient HUVECs ( Figure 5C and Figure S9 ).
| miR-139-5p inhibition is not a treatment option for CCM3 deficiency
The observation that miR-139-5p was also upregulated more than twofold in CI-huVECs upon acute CCM3 inactivation prompted us to address its function in CCM3-deficient ECs in more detail ( Figure 5C ).
Since the proangiogenic CXC chemokine receptor 4 (CXCR4) gene is a validated target of miR-139-5p, 39 we first analysed its expression in CI-huVECs upon long-term CCM3 inactivation. As expected, CXCR4 transcript levels were significantly reduced in CCM3 -/-CIhuVECs. Because re-expression of wild-type CCM3 restored CXCR4 levels, a regulatory CCM3/CXCR4 axis was assumed ( Figure 5D ). In order to further delineate the role of miR-139-5p in this axis, we silenced its signalling by transfection of a specific miRNA inhibitor ( Figure 5E ). While negative regulation of CXCR4 by miR-139-5p was intact in wild-type CI-huVECs, it was compensated in CCM3 -/-ECs ( Figure 5F ). In agreement with this observation, neither apoptosis induction nor sprouting, endothelial network formation or migration could be restored by miR-139-5p inhibition ( Figure 5G and Figure S9 ). Scale bar ≙ 200 µm. Data are presented as mean and SD (n = 3-4). Two-way ANOVA with Šidák's multiple comparisons test and Student's t test were used for statistical analysis: *P < 0.05; **P < 0.01; ****P < 0.0001 in vitro angiogenic behaviour indicates that chronic CCM3 inactiva- 58 Rescue of CXCR4 levels by adenoviral CCM3 re-expression in CCM3 -/-CI-huVECs indicates that CCM3 positively regulates CXCR4 expression. Our study therefore represents an independent experimental approach suggesting that CXCR4 downregulation might be a common consequence of CCM1 and CCM3
| DISCUSSION
inactivation. However, this regulatory axis is only partially controlled by miR-139-5p. While negative regulation of CXCR4 by miR-139-5p
was validated in wild-type CI-huVECs, it was found to be compensated after chronic CCM3 inactivation. Consequently, neither CXCR4 expression nor the dysfunctional angiogenic properties of CCM3 -/-CI-huVECs could be rescued by miR-139-5p inhibition alone. Taken together, these results support the hypothesis that miR-139-5p may modulate phenotypic variability 59 but is not a promising therapeutic target within CCM pathogenesis.
In conclusion, our genome editing study demonstrates that longterm CCM3 inactivation rather than its acute knockdown induces a clonogenic survival benefit and disturbances of endothelial network formation and angiogenic properties. This novel in vitro model may be useful to identify new therapeutic targets to block clonal expansion of mutant ECs upon chronic CCM3 depletion. 
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